Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cell & Gene Therapy
Pharma
Gilead writes $2.4B off Trodelvy as CEO underscores focus
Despite the $2.4 billion impairment charge, Gilead believes Trodelvy has a future in NSCLC.
Angus Liu
Apr 26, 2024 11:21am
Leqembi, Takeda, Fujifilm Diosynth—Fierce Pharma Asia
Apr 19, 2024 9:20am
CDMO Ascend links up with gene therapy firm Beacon Therapeutics
Apr 9, 2024 10:59am
Thermo Fisher to lay off staffers at California plasmids plant
Apr 9, 2024 8:17am
J&J, Legend's Carvykti quickly leaps ahead of BMS' rival CAR-T
Apr 8, 2024 8:30am
BMS' Abecma wins earlier myeloma nod with updated boxed warning
Apr 5, 2024 11:46am
More News
Novo, Novartis, Merck KGaA, Kyowa Kirin—Fierce Pharma Asia
Mar 22, 2024 8:45am
UPDATED: FDA advisers back Carvykti, Abecma in earlier myeloma
Mar 15, 2024 1:58pm
BIO-WuXi, Takeda, FDA-Carvykti—Fierce Pharma Asia
Mar 15, 2024 10:15am
Bristol Myers bags FDA nod to bring CAR-T to CLL
Mar 15, 2024 9:46am
See more stories